Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C6YX | ISIN: CA7594021007 | Ticker-Symbol:
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
REKLAIM LTD Chart 1 Jahr
5-Tage-Chart
REKLAIM LTD 5-Tage-Chart
PR Newswire
77 Leser
Artikel bewerten:
(0)

Reklaim Ltd.: Reklaim Reports Record Q3 Revenue with Positive EBITDA and Cash Flow Growth

Finanznachrichten News

Q3 Marks a 61% Year-over-Year Revenue Increase and Significant Progress in Financial Performance

NEW YORK, Nov. 14, 2024 /PRNewswire/ - Reklaim, (TSXV: MYID) (OTC: MYIDF) ("Reklaim"), the leading platform empowering consumers to access and reclaim their data, is pleased to announce its third-quarter results and positive EBITDA for the period ending September 30, 2024.

Key Highlights from Reklaim's Q3 2024 Performance:

  • Record Q3 Revenue: Achieved $1,487,321 for Q3 2024, up 61% year-over-year, with a nine-month total of $3,315,204, a 23% increase from 2023.
  • Positive EBITDA Growth: Reported $359,978 for Q3, reflecting a 106% increase from Q3 2023. Year-to-date EBITDA at $418,441, impacted by early-year investments in the sales team.
  • Enhanced Gross Margins: Improved to 82% for Q3 and 81% year-to-date, marking a 2-3% increase over 2023.
  • Significant Cash Flow Improvement: Positive YTD cash flow of $260,062, a 1020% increase compared to the prior year.

Strategic Achievements and Financial Strength

Reklaim's strategic focus on diversifying revenue streams has led to substantial growth across its 'Platform' and 'Deals' segments, with 'Deals' revenue surging by 3403% in Q3 2024 compared to 2023. This adaptability underscores Reklaim's ability to navigate an evolving market landscape, ensuring continued operational excellence and strategic momentum.

Neil Sweeney, Founder and CEO of Reklaim, shared, "Our Q3 2024 results affirm our strategic direction and execution capabilities. By diversifying revenue and strengthening our financial base, we're poised for continued growth. Reklaim remains steadfast in empowering consumers and driving forward in a data-driven landscape."

Looking Ahead

Reklaim continues to empower consumers to take control of their data while expanding its AI privacy initiatives. For more details on our market insights and our CEO Quarterly Letter, please review Reklaim's MD&A.

Additional

Reklaim successfully completed the conversion of $100,000 of debt into 1,111,111 shares at a deemed price of $0.09 per share on October 11, 2024, as previously disclosed in our October 10, 2024, press release.

About Reklaim

Reklaim navigates the evolving consumer data privacy landscape, providing privacy-compliant data solutions for Fortune 500 brands, platforms, and data companies. Our platform allows consumers to reclaim control over their data and be compensated through their Reklaim account. Learn more at investors.reklaimyours.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will," "may," "should," "anticipate," "expects," and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the closing of the Debt Settlement and TSXV approval of the Debt Settlement, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions in preparing forward-looking information may prove incorrect. Events or circumstances may cause actual results to differ materially from those predicted due to numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and the reader is cautioned not to place undue reliance on any forward-looking information. Although considered reasonable by management during preparation, such information may prove incorrect, and actual results may differ materially from those anticipated. This cautionary statement expressly qualifies forward-looking statements contained in this news release. The forward-looking statements in this news release are made as of the date of this news release. The Company will only update or revise any included forward-looking statements as expressly required by Canadian securities law.

SOURCE Reklaim Ltd.

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.